Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Textual)

v3.8.0.1
Significant Accounting Policies (Details Textual) - USD ($)
$ in Millions
 1 Months Ended 10 Months Ended 12 Months Ended
Mar. 13, 2017
Jul. 31, 2016
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired           $ 9.6  
Property Plant And Equipment Design Costs Capitalized           1.2  
Certificates of Deposit, at Carrying Value           $ 40.0  
Certificates Of Deposits, 250,000 or Less, Description           the Company had approximately $40.0 million in certificates of deposit with no more than $250,000 at any individual institution.  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent       35.00%   35.00% 35.00%
Scenario, Plan [Member]              
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent         21.00%    
Held-to-maturity Securities [Member]              
Time Deposits, at Carrying Value           $ 26.0  
Cash and Cash Equivalents [Member]              
Time Deposits, at Carrying Value           $ 14.0  
Fortress Biotech, Inc [Member]              
Annual Fee On Diluted Outstanding Equity, Percentage           2.50%  
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired     $ 0.2     $ 9.6 $ 4.4
Stock Issued During Period, Shares, Issued for Services 767,264            
Series A Preferred Stock [Member]              
Stock Issued During Period, Shares, Issued for Services           0 0
Series A Preferred Stock [Member] | Fortress Biotech, Inc [Member]              
Stock Issued During Period, Shares, Issued for Services   250,000          
Preferred Stock, Dividend Rate, Percentage   2.50%